Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
06/2002
06/13/2002US20020072540 For therapy, prophylaxis and diagnosis of respiratory distress syndrome or other pulmonary diseases that are associated with deficiency of lung surfactant
06/13/2002US20020072503 Compositions and methods for the therapy and diagnosis of ovarian cancer
06/13/2002US20020072499 Specifically an N-formyl-methionyl-leucyl ("f-Met-Leu") tri-or tetra-peptide; pathological fibrosis or those caused by trauma or surgery
06/13/2002US20020072498 Method for administering ciliary neurotrophic factor to the brain
06/13/2002US20020072497 Novel DNA and recombinant production of novel polypeptides
06/13/2002US20020072496 Secreted and transmembrane polypeptides and nucleic acids encoding the same
06/13/2002US20020072495 LL-37 is an immunostimulant
06/13/2002US20020072494 Angiogenesis inhibitor, K1-5 (protease-activated kringles 1-5) genetically engineered so it can be secreted from cells in which it is expressed; contains a secretory signal peptide and a pre-activation peptide derived from plasminogen
06/13/2002US20020072493 To promote nerve regeneration or to confer neuroprotection by administering the T cells or a nervous system-specific antigen such as myelin basic protein
06/13/2002US20020072489 Fibroblast growth factors (FGF); single unit dosage; treating coronary artery disease (atherosclerosis)
06/13/2002US20020072488 Amino acid sequences of human transporter peptides and proteins that are related to the sugar transporter subfamily; identifying modulators of the transporter peptides
06/13/2002US20020072487 Method for searching physiologically active substances, process for producing these substances and drugs found by the searching method
06/13/2002US20020072115 Pancreatic islet cell growth factors
06/13/2002US20020072107 Human osteoclast derived cathepsin
06/13/2002US20020072101 Novel human nucleic acid molecules and polypeptides encoding cation channels
06/13/2002US20020072092 Secreted and transmembrane polypeptides and nucleic acids encoding the same
06/13/2002US20020072091 Death domain containing receptor 5
06/13/2002US20020072090 Hr-1 receptor
06/13/2002US20020072089 Novel ITALY, Lor-2, STRIFE, TRASH, BDSF, LRSG, and STMST protein and nucleic acid molecules and uses therefor
06/13/2002US20020072067 Secreted and transmembrane polypeptides and nucleic acids encoding the same
06/13/2002US20020072052 Compositions and methods for regulating bacterial pathogenesis
06/13/2002US20020071873 Purified growth factor in a concentration of less than 1 x 10-6 molar.
06/13/2002US20020071862 Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis, and pharmaceutical compositions, and kit related thereto
06/13/2002US20020071849 A41L protein or a chemokine-binding fragment thereof; detecting an interaction of the chemokine-binding molecule with a chemokine; antiinflammatory agents
06/13/2002US20020071841 Recombinant toxin and monoclonal antibody which specifically binds to glial-derived or meningioma-derived tumor cells; screening for malignant gliomas and meningiomas; treating glioblastoma multiforme and astrocytomas.
06/13/2002US20020071840 Method of therapeutic administration of anti-CD40L compounds
06/13/2002US20020071838 Method for raising the blood glucose level in mammals
06/13/2002US20020071837 Preferred hyaluronidase enzyme is devoid of molecular weight fractions below 40,000 MW, between 60-70,000 MW and above 100,OOO MW
06/13/2002US20020071836 Preferred sugar-processing enzymes are cellulases and glucolytic enzymes.
06/13/2002US20020071833 Hematopoietic stem cell gene therapy
06/13/2002US20020071832 Use of mutant herpes viruses and anticancer agents in the treatment of cancer
06/13/2002US20020071831 Chlamydia antigens and corresponding DNA fragments and uses thereof
06/13/2002US20020071830 Expression vector is used to express a polypeptide comprising the core protein of a human polymorphic epithelial mucin, which core protein is specifically bound by monoclonal antibody, SM3.
06/13/2002US20020071829 Normalization of defective T cell responsiveness through manipulation of thymic regeneration
06/13/2002US20020071828 Biocompatible cuff into which a system for expressing a neurotrophic factor is introduced.
06/13/2002US20020071825 Methods and compositions for inducing an immune response
06/13/2002US20020071824 Gene transfer to pancreatic b cells for prevention of islet dysfunction
06/13/2002US20020071814 Administering a compound that either inhibits the synthesis of ceramide, blocks the activity of ceramide, or degrades ceramide.
06/13/2002US20020071807 Immunotherapy of B-cell malignancies using anti-CD22 antibodies
06/13/2002DE10059336A1 Herstellung von rekombinantem BMP-2 Production of recombinant BMP-2
06/13/2002DE10051983A1 Medicaments useful e.g. for preventing thrombosis, inhibiting transplant rejection or treating chronic inflammatory reactions comprises agents inhibiting binding of oxidized proteins to CD36,
06/13/2002CA2716959A1 Glp-1 fusion proteins
06/13/2002CA2436847A1 Treatment of cancer by reduction of intracellular energy and pyrimidines
06/13/2002CA2436732A1 Protein modification and maintenance molecules
06/13/2002CA2436666A1 Use of zwitterionic polysaccharides for the specific modulation of immune processes
06/13/2002CA2436519A1 Selection of catalytic nucleic acids targeted to infectious agents
06/13/2002CA2436306A1 Basb221 polypeptides and polynucleotides encoding basb221 polypeptides
06/13/2002CA2431374A1 Novel fibroblast growth factors
06/13/2002CA2431203A1 Polypeptide sequences of drug metabolizing enzymes and polynucleotide sequences coding therefor
06/13/2002CA2431193A1 Sequences upstream of the carp gene, vectors containing them and uses thereof
06/13/2002CA2431179A1 Synthesis of small particles
06/13/2002CA2430998A1 Expression of keratin genes 8 and 18 for treating tumours, in particular a mammary carcinoma
06/13/2002CA2430993A1 G-protein coupled receptors
06/13/2002CA2430948A1 Caml-binding peptides
06/13/2002CA2430716A1 Nucleic acids of the human abca5, abca6, abca9, and abca10 genes, vectors containing such nucleic acids and uses thereof
06/13/2002CA2430624A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
06/13/2002CA2430621A1 Vaccine composition containing transforming growth factor alpha
06/13/2002CA2430558A1 Proteins and nucleic acids encoding same
06/13/2002CA2430379A1 Endogenous retroviruses up-regulated in prostate cancer
06/13/2002CA2430191A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
06/13/2002CA2429959A1 Adipocyte complement related protein zacrp3x2
06/13/2002CA2429769A1 Methods of treatment involving human mda-7
06/13/2002CA2429641A1 Kinases and phosphatases
06/13/2002CA2429094A1 Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
06/13/2002CA2428390A1 Enzymes
06/13/2002CA2428208A1 Lipid-associated molecules
06/13/2002CA2428097A1 Immunomodulatory protein derived from the yaba monkey tumor virus
06/13/2002CA2428092A1 Use of sarp-1 for the treatment and/or prevention of scleroderma
06/13/2002CA2425396A1 Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins)
06/12/2002EP1213353A1 Peptide leukotriene receptor
06/12/2002EP1213352A1 Nucleic acids of the human abca5, abca6, abca9, and abca10 genes, vectors containing such nucleic acids and uses thereof
06/12/2002EP1213351A2 Nucleic acid enzymes acquiring an activity for cleaving a target RNA by recognising another molecule
06/12/2002EP1213348A2 Parasite-derived resistance
06/12/2002EP1213299A1 Immunogenic epitopes of human papilloma virus and uses thereof
06/12/2002EP1213298A1 Antibiotics GE 23077, pharmaceutically acceptable salts and compositions, and use thereof
06/12/2002EP1213297A1 Novel tachykinin peptides, precursor peptides thereof and genes encoding the same
06/12/2002EP1213032A1 Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
06/12/2002EP1213029A1 Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
06/12/2002EP1213028A1 Hm1.24 antigen expression potentiators
06/12/2002EP1213024A1 Cosmetic and/or dermopharmaceutical composition containing native proteins of Argania spinosa
06/12/2002EP1212941A2 Modulating ramp activity
06/12/2002EP1212464A2 Diagnostics and therapeutics for osteoporosis
06/12/2002EP1212456A1 Antisense modulation of shp-2 expression
06/12/2002EP1212455A1 Antisense modulation of telomeric repeat binding factor 1 expression
06/12/2002EP1212436A2 Protein phosphatase and kinase proteins
06/12/2002EP1212434A2 Human hydrolytic enzymes
06/12/2002EP1212433A2 Protein phosphatases and diagnosis and treatment of phosphatase-related disorders
06/12/2002EP1212423A2 Identification of the domain of plasmodium falciparum erythrocyte membrane protein 1 (pfemp1) that mediates adhesion to chondroitin sulfate a
06/12/2002EP1212422A2 Human ctla-4 antibodies and their uses
06/12/2002EP1212421A1 Gas1 polypeptides
06/12/2002EP1212420A1 Conditional immortalisation of cells
06/12/2002EP1212419A2 Polycyclic aromatic hydrocarbon induced molecules
06/12/2002EP1212418A2 p193 PROTEINS AND NUCLEIC ACIDS, AND USES THEREOF
06/12/2002EP1212417A2 Interleukin-1-receptor associated kinase-3 (irak3)
06/12/2002EP1212416A2 Nucleic acid based modulators of gene expression
06/12/2002EP1212415A1 Pgrp-l polynucleotides, polypeptides, and antibodies
06/12/2002EP1212414A2 Polypeptides capable of interacting with the smad peptide and comprising the sequence pp(t/n)k
06/12/2002EP1212410A2 Dna encoding the human serine protease eos
06/12/2002EP1212407A1 Immunoglobulin superfamily polynucleotides, polypeptides, and antibodies
06/12/2002EP1212404A2 Isolation of muscle-derived stem cells and uses therefore